It is notable that the industry spends more on marketing than R&D. Virtually all of this spend is in the US; very few countries allow the marketing of prescription drugs to consumers.

Quite a bit of the high pricing for Americans is also by companies who _don’t even do_ R&D to any significant extent; companies who only make generic price them dramatically higher in the US than elsewhere.